Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 13, 2025
Product Development
Managing Novartis’ pipeline in an era of fast innovation: Vas Narasimhan in conversation
How the pharma CEO views precision medicine, rising challenges in radioligand therapy, and the CAR T immune reset opportunity
BioCentury | Mar 6, 2025
Product Development
Telix’s end-to-end radiopharma ambitions
With a NASDAQ listing, diagnostic revenues, and clinical therapeutics, logistics-forward company aims to own entire disease journey
BioCentury | Feb 4, 2025
Finance
Australian radiopharma play Advancell taps VCs for $112M in ‘scale capital’
Expanding in U.S., the biotech will build manufacturing capacity for α-emitters, including clinical program for prostate cancer
BioCentury | Dec 30, 2024
Product Development
The uncertainty principle: Hello, 2025
BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025
BioCentury | Dec 4, 2024
Product Development
Confidence in masked T cell engagers builds with Janux update
Also in BioCentury’s Clinical Report: Cartesian’s autoimmune CAR T durability, Roivant’s miss, Novocure’s pancreatic cancer data, and more
BioCentury | Nov 21, 2024
Product Development
Companies get creative with multi-targeted CARs at SITC, ASH
BioCentury’s analysis of the SITC, ASH abstracts highlights progress in bicistronic and tandem CAR Ts
BioCentury | Nov 20, 2024
Deals
Where the Ratio deal fits into Novartis’ radiopharma matrix
The deal grows Novartis’ ligand modality and chelator toolbox, and its focus on Lutathera target SSTR2
BioCentury | Oct 31, 2024
Finance
Axonis advancing KCC2 program with $115M series A
BioCentury’s Venture Report also includes fundings for Evommune, Blue Earth and more
BioCentury | Oct 7, 2024
Deals
AstraZeneca, Hong Kong-based CSPC in deal for dyslipidemia therapy
Deals report: Recordati acquires Enjaymo from Sanofi, and updates from BioMarin-Camp4, Editas-DRI and more
BioCentury | Aug 13, 2024
Product Development
Vir evolves from antiviral one-stop shop to protein engineering play
Shedding non-protein platforms and bringing in masked bispecifics for cancer, the company’s pivot highlights the challenges of its founding thesis.
Items per page:
1 - 10 of 322